- Home
- CATO vs TELO Comparison
CATO vs TELO Comparison
Compare CATO & TELO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATO
- TELO
- Stock Information
- Founded
- CATO 1946
- TELO 2021
- Country
- CATO United States
- TELO United States
- Employees
- CATO N/A
- TELO N/A
- Industry
- CATO Clothing/Shoe/Accessory Stores
- TELO
- Sector
- CATO Consumer Discretionary
- TELO
- Exchange
- CATO Nasdaq
- TELO NYSE
- Market Cap
- CATO 118.4M
- TELO 124.1M
- IPO Year
- CATO N/A
- TELO 2024
- Fundamental
- Price
- CATO $3.66
- TELO $4.24
- Analyst Decision
- CATO
- TELO
- Analyst Count
- CATO 0
- TELO 0
- Target Price
- CATO N/A
- TELO N/A
- AVG Volume (30 Days)
- CATO 129.2K
- TELO 88.1K
- Earning Date
- CATO 11-21-2024
- TELO 11-12-2024
- Dividend Yield
- CATO 18.73%
- TELO N/A
- EPS Growth
- CATO N/A
- TELO N/A
- EPS
- CATO N/A
- TELO N/A
- Revenue
- CATO $666,779,000.00
- TELO N/A
- Revenue This Year
- CATO N/A
- TELO N/A
- Revenue Next Year
- CATO N/A
- TELO N/A
- P/E Ratio
- CATO N/A
- TELO N/A
- Revenue Growth
- CATO N/A
- TELO N/A
- 52 Week Low
- CATO $3.35
- TELO $3.11
- 52 Week High
- CATO $7.80
- TELO $20.72
- Technical
- Relative Strength Index (RSI)
- CATO 24.18
- TELO 47.97
- Support Level
- CATO $5.73
- TELO $3.20
- Resistance Level
- CATO $6.30
- TELO $4.95
- Average True Range (ATR)
- CATO 0.36
- TELO 0.50
- MACD
- CATO -0.24
- TELO 0.07
- Stochastic Oscillator
- CATO 9.47
- TELO 59.54
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories primarily in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About TELO TELOMIR PHARMACEUTICALS INC
Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.